Telehealth Effective for Nutrition Therapy in Patients With Hyperlipidemia
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 9, 2024 -- Telehealth may be an effective means to increase access to medical nutrition therapy for patients with hyperlipidemia, according to a study published online Nov. 16 in the Journal of Clinical Lipidology.
Shannon Zoulek, M.D., from the University of Michigan in Ann Arbor, and colleagues compared previsit to postvisit change in lipid markers of virtual (41 patients) versus face-to-face (151 patients) visits with a registered dietitian nutritionist for treating hyperlipidemia.
The researchers found that during a median 33 days, there was a significant decrease in total cholesterol, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol for both visit types. However, there were no significant differences in mean change in lipid markers between the two visit types.
"Access to nutrition care is crucial, and our study shows just how effective virtual care can be for helping improve cholesterol levels," coauthor Beverly Kuznicki, R.D.N., also from the University of Michigan, said in a statement. "Virtual care welcomes the dietitian into the patient's kitchen where the two can work together to come up with a nutrition plan which focuses on foods that are already in their pantry and refrigerator."
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.